QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18-70
SponsorTianjin Medical University Cancer Institute and Hospital
About this trial
This is a prospective, single-arm, multicenter Phase II study evaluating the efficacy and safety of QL1706 combined with chemotherapy in patients with advanced recurrent or metastatic endometrial cancer who progressed after prior anti-PD-1/L1 therapy.
Eligibility criteria
Qualifiers
Age ≥18 years and ≤70 years.
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
Recurrent or metastatic endometrial carcinoma, confirmed by pathology or imaging.
At least one measurable tumor lesion according to RECIST v1.1 criteria.
Disqualifiers
1. Previous treatment with PD-1/CTLA-4 dual-target immunotherapy, immune checkpoint agonists (e.g., ICOS, CD40, CD137, GITR, OX40 antibodies, etc.), or immune cell therapy.
Trial design
Treatments tested in this trial
- QL1706 combined with chemotherapy ± Bevacizumab
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov